Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 5346 | 1310726-60-3 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 23, 2020 | PMDA | AbbVie GK | |
Aug. 16, 2019 | FDA | ABBVIE INC | |
Dec. 16, 2019 | EMA | AbbVie Deutschland GmbH & Co. KG |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Therapy interrupted | 404.42 | 29.09 | 86 | 1203 | 10705 | 46674068 |
COVID-19 | 171.27 | 29.09 | 48 | 1241 | 18527 | 46666246 |
Urinary tract infection | 53.79 | 29.09 | 46 | 1243 | 220220 | 46464553 |
Herpes zoster | 41.85 | 29.09 | 25 | 1264 | 67847 | 46616926 |
Illness | 31.24 | 29.09 | 12 | 1277 | 12212 | 46672561 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Therapy interrupted | 83.65 | 38.97 | 17 | 294 | 4512 | 29947655 |
COVID-19 | 42.69 | 38.97 | 13 | 298 | 17865 | 29934302 |
Source | Code | Description |
---|---|---|
ATC | L04AA44 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D000075242 | Janus Kinase Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.85 | acidic |
pKa2 | 12.79 | acidic |
pKa3 | 3.25 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
15MG | RINVOQ | ABBVIE INC | N211675 | Aug. 16, 2019 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 16, 2024 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase JAK1 | Kinase | INHIBITOR | IC50 | 7.33 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Tyrosine-protein kinase JAK2 | Kinase | INHIBITOR | IC50 | 6.92 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Tyrosine-protein kinase JAK3 | Kinase | INHIBITOR | IC50 | 5.63 | SCIENTIFIC LITERATURE | DRUG LABEL |
ID | Source |
---|---|
4038662 | VANDF |
C4308782 | UMLSCUI |
CHEMBL3622821 | ChEMBL_ID |
CHEMBL3707269 | ChEMBL_ID |
58557659 | PUBCHEM_CID |
D10994 | KEGG_DRUG |
C000613732 | MESH_SUPPLEMENTAL_RECORD_UI |
10209 | INN_ID |
DB15091 | DRUGBANK_ID |
4RA0KN46E0 | UNII |
9246 | IUPHAR_LIGAND_ID |
2196092 | RXNORM |
321410 | MMSL |
37314 | MMSL |
d09350 | MMSL |
018092 | NDDF |
789397000 | SNOMEDCT_US |
789416006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Rinvoq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-2306 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | NDA | 29 sections |